定坤丹联合米非司酮对子宫内膜异位症术后患者促血管生长因子及血清肿瘤标志物水平的影响

Effects of Dingkundan combined with mifepristone on levels of vascular endothelial growth factor and serum tumor markers in endometriosis patients after surgery

目的探讨子宫内膜异位症术后患者采用定坤丹联合米非司酮治疗对促血管生长因子、血清肿瘤标志物水平的影响。方法86例子宫内膜异位症术后患者作为研究对象,根据入院顺序的奇偶性交叉分为参照组及验证组,每组43例。参照组采用米非司酮治疗,验证组采用定坤丹联合米非司酮治疗。对比两组患者治疗前后的血清肿瘤标志物[糖类抗原199(CA199)、糖类抗原125(CA125)、抗子宫内膜抗体(EMab)]及促血管生长因子[碱性成纤维细胞生长因子(bFGF)、血管内皮生长因子-A(VEGF-A)、转化生长因子β1(TGF-β1)]水平,不良反应发生情况。结果治疗后,两组患者的CA199、CA125、EMab水平均低于本组治疗前,且验证组患者的CA199(29.43±3.16)U/ml、CA125(27.06±2.97)U/ml、EMab(0.24±0.03)ng/L均低于参照组的(34.31±3.82)U/ml、(31.42±3.46)U/ml、(0.33±0.04)ng/L,差异具有统计学意义(P<0.05)。治疗后,两组患者的bFGF、VEGF-A、TGF-β1水平均低于本组治疗前,且验证组患者的bFGF(95.68±15.42)μg/L、VEGF-A(369.46±36.25)pg/ml、TGF-β1(36.33±3.23)μg/L均低于参照组的(118.95±18.34)μg/L、(477.03±42.17)pg/ml、(41.68±4.31)μg/L,差异具有统计学意义(P<0.05)。治疗期间,验证组不良反应发生率为13.95%(6/43),略高于参照组的9.30%(4/43),但差异无统计学意义(P>0.05)。结论子宫内膜异位症术后患者实施定坤丹联合米非司酮治疗,能明显降低其促血管生长因子和血清肿瘤标志物水平,且不会明显增加患者服药期间的不良反应,应用价值显著。

Objective To discuss the effects of Dingkundan combined with mifepristone on levels of vascular endothelial growth factor and serum tumor markers in endometriosis patients after surgery.Methods A total of 86 endometriosis patients after surgery were studied and divided into the reference group and the validation group according to the parity crossing of admission order,with 43 cases in each group.The reference group was treated with mifepristone,and the validation group was treated with Dingkundan and mifepristone.Both groups were compared in terms of levels of serum tumor markers[carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125),anti-endometrial antibodies(EMab)]and vascular endothelial growth factors[basic fibroblast growth factor(bFGF),vascular endothelial growth factor-A(VEGF-A),transforming growth factor-β1(TGF-β1)]before and after treatment,and occurrence of adverse reactions.Results After treatment,the levels of CA199,CA125 and EMab in both groups were lower than those before treatment in this group;verification group had CA199 of(29.43±3.16)U/ml,CA125 of(27.06±2.97)U/ml and EMab of(0.24±0.03)ng/L,which were lower than those of(34.31±3.82)U/ml,(31.42±3.46)U/ml and(0.33±0.04)ng/L in the reference group;the differences were statistically significant(P<0.05).After treatment,the levels of bFGF,VEGF-A and TGF-β1 in both groups were lower than those before treatment in this group;verification group had bFGF of(95.68±15.42)μg/L,VEGF-A of(369.46±36.25)pg/ml and TGF-β1 of(36.33±3.23)μg/L,which were lower than those of(118.95±18.34)μg/L,(477.03±42.17)pg/ml and(41.68±4.31)μg/L in the reference group;the differences were statistically significant(P<0.05).During treatment,the incidence of adverse reactions in the verification group was 13.95%(6/43),which was slightly higher than that of 9.30%(4/43)in the reference group,but the difference was not statistically significant(P>0.05).Conclusion Combined application of Dingkundan and mifepristone is of great value in the treatment of endometriosis patients after surgery,which can significantly reduce the levels of vascular endothelial growth factor and serum tumor markers,and will not significantly increase the adverse reactions of patients during medication.